APA (7th ed.) Citation

P, T., N, T., G, V., C, D., DA, Y., SJ, I., . . . SM, T. (2024). Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 42(31), 3652. https://doi.org/10.1200/JCO.23.02170

Chicago Style (17th ed.) Citation

P, Tarantino, et al. "Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 42, no. 31 (2024): 3652. https://doi.org/10.1200/JCO.23.02170.

MLA (9th ed.) Citation

P, Tarantino, et al. "Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 42, no. 31, 2024, p. 3652, https://doi.org/10.1200/JCO.23.02170.